| Literature DB >> 27366593 |
Jingchen Shao1, Susann Li1, Lars Palmqvist1, Linda Fogelstrand1, Stella Y Wei2, Kiran Busayavalasa3, Kui Liu3, Viktor M Liu1.
Abstract
PTEN acts as a phosphatase for PIP3 and negatively regulates the PI3K/AKT pathway, and p27(KIP1) is a cyclin-dependent kinase inhibitor that regulates the G1 to S-phase transition by binding to and regulating the activity of cyclin-dependent kinases. Genetic alterations of PTEN or CDKN1B (p27(KIP1)) are common in hematological malignancies. To better understand how mutations in these two genes might cooperate in leukemogenesis, we inactivated both genes in the hematological compartment in mice. Here, we show that the combined inactivation of Pten and Cdkn1b results in a more severe myeloproliferative neoplasm phenotype associated with lower hemoglobin, enlarged spleen and liver, and shorter lifespan compared to inactivation of Pten alone. More severe anemia and increased myeloid infiltration and destruction of the spleen contributed to the earlier death of these mice, and elevated p-AKT, cyclin D1, and cyclin D3 might contribute to the development of this phenotype. In conclusion, PTEN and p27(KIP1) cooperate in tumor suppression in the hematological compartment.Entities:
Keywords: Myeloproliferative neoplasms; PTEN; p27KIP1
Year: 2016 PMID: 27366593 PMCID: PMC4928343 DOI: 10.1186/s40164-016-0047-0
Source DB: PubMed Journal: Exp Hematol Oncol ISSN: 2162-3619
Fig. 1Survival, white blood cell counts, hemoglobin level, and histological analysis of all groups of mice. a Kaplan–Meier survival plots for PCM (n = 6), PM (n = 12), CM (n = 12) and Ctrl mice (n = 12). b White blood cell counts of PCM, PM, CM and Ctrl mice (n = 8 in each group). Blood was analyzed before and 1 and 2 weeks after pI–pC injections. c Blood hemoglobin concentrations of mice at 3 weeks after pI–pC injections. d Photographs of bone marrow (top panels) and spleen (bottom panels) sections (hematoxylin and eosin staining). Magnification was ×100/1.40 for bone marrow, ×20/0.50 for spleens
Fig. 2PCM mice exhibit massive hepatosplenomegaly, extramedullary hematopoiesis, and increased colony growth of splenocytes. a Spleen and b liver weight [relative to total body weight (bwt)] in PCM (n = 5), PM (n = 5), CM (n = 5), and Ctrl (n = 5) mice 3 weeks after pI–pC injections. c Colony-forming ability of splenocytes isolated from PCM (n = 3), PM (n = 3), CM (n = 3) and Ctrl (n = 3) mice around 3 weeks after pI–pC injections. GEMM colony-forming unit-granulocyte, erythroid, macrophage, megakaryocyte, GM colony-forming unit-granulocyte, macrophage, E burst-forming unit-erythroid. d Representative flow cytometry plots of splenocytes with antibodies recognizing CD11b, Gr-1, c-Kit, Sca1 and Lineage-negative. The mean percentage of double-positive splenocytes from PCM (n = 3), PM (n = 3), CM (n = 3), and Ctrl (n = 3) mice is indicated. e Percentage of LSK cells in bone marrow from PCM (n = 3), PM (n = 3), CM (n = 3), and Ctrl (n = 3) mice, as determined with flow cytometry. f Colony-forming ability of bone marrow from PCM (n = 3), PM (n = 3), CM (n = 3), and Ctrl (n = 3) mice. g Western blots of protein extracts from splenocytes of PCM (n = 2), PM (n = 2), CM (n = 2), and Ctrl (n = 2) mice at the 3rd week after pI–pC injection. Actin was used as the loading control